Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology (Q36711702)

15 August 2017

title

Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology (English)

1 reference

15 August 2017

P Régine Mydlarski

1

1 reference

15 August 2017

Vincent Ho

series ordinal

2

1 reference

15 August 2017

Neil H Shear

series ordinal

3

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Journal of cutaneous medicine and surgery

15 August 2017

published in

1 reference

15 August 2017

volume

10

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

205-221

1 reference

Side effects of corticosteroid therapy

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The use of systemic immune moderators in dermatology: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Clinical uses of intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Dermatological Uses of High-Dose Intravenous Immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Immunomodulatory action of intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Differences between IGIV products: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Pemphigus and bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Immunofluorescence in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Immunosuppressants in the treatment of pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Management of autoimmune bullous diseases: pharmacology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Blistering disorders: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Bullous pemphigoid: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A 230-kD basic protein is the major bullous pemphigoid antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The role of complement in experimental bullous pemphigoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Pemphigus and pemphigoid. A review of the advances made since 1964.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Autoimmune blistering diseases: an up-date of diagnostic methods and investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Treatment of subepidermal immunobullous diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Guidelines for the management of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

High Risk of Death in Elderly Patients With Extensive Bullous Pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Minocycline as a therapeutic option in bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

21 January 2018

Cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Epidermolysis bullosa acquisita: update and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Emerging treatment for epidermolysis bullosa acquisita

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Epidermolysis bullosa acquisita responsive to cyclosporin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Toxic epidermal necrolysis: current evidence, practical management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Severe adverse cutaneous reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Risk of Stevens-Johnson syndrome and toxic epider mal necrolysis during first weeks of antiepileptic therapy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Drug-induced toxic epidermal necrolysis treated with cyclosporin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Controversy: are systemic steroids indicated in the treatment of erythema multiforme?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Toxic epidermal necrolysis: does immunoglobulin make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Chronic urticaria: aetiology, management and current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

Psoriasis: response to high-dose intravenous immunoglobulin in three patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2310/7750.2006.00048

21 January 2018

Identifiers

DOI

10.2310/7750.2006.00048

1 reference

release_xrg2fszzizeyxbzwaq6zzalm2i

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xrg2fszzizeyxbzwaq6zzalm2i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference